

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/107, 31/015, 31/355	A1	(11) International Publication Number: WO 94/21231 (43) International Publication Date: 29 September 1994 (29.09.94)
(21) International Application Number: PCT/AU94/00141 (22) International Filing Date: 22 March 1994 (22.03.94) (30) Priority Data: PL 7934 22 March 1993 (22.03.93) AU (71) Applicant (for all designated States except US): BETATENE LIMITED [AU/AU]; A.C.N. 006 374 456, 71-73 Taunton Drive, Cheltenham, VIC 3192 (AU). (72) Inventor; and (75) Inventor/Applicant (for US only): SCHLIPALIUS, Lance, Elliot [AU/AU]; 14 Delta Avenue, Ashwood, VIC 3147 (AU). (74) Agent: McMASTER, Wayne; Freehill Patent Services, Level 47, 101 Collins Street, Melbourne, VIC 3000 (AU).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: THERAPEUTIC AGENT FOR THE TREATMENT OF MELANOMAS (57) Abstract A therapeutic agent for the treatment of a melanoma or melanomas by injection or intravenously including a mixture of: (a) a water soluble dispersible component; (b) an emulsifier component; and (c) a water insoluble carotenoid component in a suitable carrier medium.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Therapeutic Agent for the Treatment of Melanomas

Field of the Invention

The invention relates to a therapeutic agent for the treatment of a melanoma or melanomas and a method for such treatment.

5 Background of the Invention

Melanomas are caused generally by the exposure of skin to sunlight. Persons of fair complexion have the greatest risk especially those who develop moles.

Melanomas originate from a change in normal skin cells, melanocytes, which produce the brown pigment melanin we recognise as tan. Moles and freckles result from areas of the
10 skin with many melanocytes.

The influence of light on melanocytes is one way by which they can be changed to grow and divide differently, possibly causing a melanoma. The melanomas may be malignant, spreading to other parts of the body. Melanomas which do not spread are called benign.

Although melanomas normally form on exposed skin they can start in places such as the
15 mouth or bowel.

Melanomas grow in size and need to be surgically removed before they spread and invade other parts of the body. If the melanomas spread to the inner organs, removal and treatment is more difficult and chemotherapy or radiotherapy need to be employed.

It has been hypothesised that carotenoids and in particular beta-carotene may reduce the
20 risk of breast, lung, colon, prostate and cervical cancer, heart disease and stroke and may retard macular degeneration. In this respect, one hypothesis is that in mammals beta-carotene is converted to vitamin A and vitamin A analogues or retinoids (see Moon RC: Comparative aspects of carotenoids and retinoids as chemopreventive agents for cancer. J Nutr 119:127-134, 1989). It is this pro-vitamin A activity and the ability to
25 prevent oxidative damage that has made carotenoids and in particular beta-carotene a compound of interest in chemopreventive studies. For instance, anti-oxidants are used, amongst other things, to quench free radicals that are by-products of normal metabolism in cells.

Beta-carotene has also been used in the treatment of erythropoietic protoporphyria (EPP).
30 EPP is a genetic disease causing an inadequacy in the metabolism of porphyrin compounds. It results in a rapid blistering of the skin on exposure to sunlight.

When considering the use of carotenoid compositions for human application an immediate difficulty arises as a result of the nature of carotenoids.

Carotenoids are lipophilic and therefore not soluble in water in useful quantities. It is believed that they are transported in the bloodstream as low density lipoproteins.

5 The current principal means by which carotenoids are introduced into the body is orally. However, this method is often unsatisfactory because the poor absorption of the carotenoid composition by the alimentary canal limits the concentrations in the blood which can be achieved. Further, there will be a substantial delay before a required level of carotenoids in the bloodstream or a specific organ is reached. Sometimes the required level cannot be
10 reached as certain individuals do not absorb carotenoids very well, especially beta-carotene. There is about a tenfold difference in the ability of human individuals to absorb beta-carotene. There have been over 500 carotenoids isolated, but only approximately 15 have been shown to occur in the bloodstream.

Physicians often seek to administer compounds by injection or by intravenous drip rather
15 than oral ingestion. However, because of the virtual water insolubility of carotenoid compositions it is very difficult to administer them either by injection or intravenously. The compound must be made dispersible in an aqueous base so that it is available to the body's cells. In this regard, the base must be compatible with, for example, the bloodstream or lymph, and the material must be prepared in a biologically sterile form. The base must
20 itself be non-toxic to the human cells.

To date several in vitro studies have taken place to determine the effect of beta-carotene on normal and transformed cell types using solvents to solubilise the beta-carotene such as tetrahydrofuran, butanol, chloroform, hexane, dimethylsulfoxide, ethanol or in a liposome micelle. Previous liposome preparations have shown toxicity in cell line cultures as well as
25 being limited in application (see Bertram JS, Pung A, Churley M, et al: Diverse carotenoids protect against chemically induced neoplastic transformation. Carcinogenesis 12:671-678, 1991; Hazuka MB, Prasad-Edwards J, Newman F, et al: Beta-carotene induces morphological differentiation and decreases adenylate cyclase activity in melanoma cells in culture. J Am Coll Nutr 9:143-149, 1990; Schultz TD, Chew BP, Seaman WR, et al: Inhibitory effect of conjugated dienoic derivatives of linoleic acid and
30 beta-carotene on the in vitro growth of human cancer cells. Canc Letters 63:125-133, 1992; Schwartz JL, Shklar G: The selective cytotoxic effect of carotenoids and a-tocopherol on human cancer cell lines in vitro. J Oral Maxillofac Surg 50:367-373, 1992; Schwartz JL, Tanaka J, Khandekar V, et al: Beta-Carotene and/or Vitamin E as modulators
35 of alkylating agents in SCC-25 human squamous carcinoma cells. Canc Chemother

Pharmacol 29:207-213, 1992; Zhang L-X, Cooney RV, Bertram JS: Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: relationship to their cancer chemopreventive action. Carcinogenesis 12:2109-2114, 1991; and Zhang L-X, Cooney RV, Bertram JS: Carotenoids up-regulate connexin 43 gene
5 expression independent of their provitamin A or antioxidant properties. Canc Res 52:5707-5712, 1992). These solvents have been found to have a toxic effect which is dose dependent. These solvents are also incompatible with human blood or lymph for the purposes of intravenous or injectable preparations.

Accordingly, investigations were carried out to develop a carotenoid composition which
10 could be accepted by the human body and other animals and display efficacy in the treatment of melanomas.

Description of the Invention

In one embodiment of the invention a therapeutic agent is provided for the treatment of a melanoma or melanomas including a mixture of:

- 15 (a) a water soluble or dispersible component;
- (b) an emulsifier component; and
- (c) a water insoluble carotenoid component in a suitable carrier medium.

Preferably, the water soluble or dispersible component is in the range of 30% to 90% by weight.

20 In a further preferred form of the invention, the water soluble or dispersible component is selected from sugar alcohols, sugars, amino acids, water, vitamins, blood serum or plasma, lymph, buffers and combinations and polymers of these materials, and injectables that are well known in the industry such as mineral salt preparations and dextrose solutions or combinations of these components.

25 More preferably, the sugar alcohol is glycerol and in yet a further preferred embodiment, glycerol is in the range of 30% to 90% by weight.

In yet a further preferred form of the invention, the emulsifier component is in the range of 0.2% to 20% by weight and more preferably 1.0% to 10% by weight.

In yet another further preferred embodiment of the invention, the emulsifier component is
30 selected from glycerides (including preferably monoglyceride and diglyceride structures from plant and animal sources), polyglycerol esters, lecithins and other phospholipids. More preferably the glyceride is glyceryl mono-oleate.

In another preferred form of the invention, the water insoluble carotenoid component is beta carotene. In yet a further preferred form that water insoluble carotenoid component comprises a predominantly 2% to 50% by weight beta-carotene in soya bean oil composition. More preferably, the beta carotene concentration is a predominantly 20% to 40% by weight and most preferably predominantly 30% by weight.

Preferably, the beta-carotene is a mixture of cis beta-carotene and all trans beta-carotene. Typically, the cis beta-carotene content of the beta-carotene is in the range of 50% and 90%, more preferably 70% and 85%. More preferably, the beta-carotene is predominantly 9 cis beta-carotene in a preferred range of 60% to 90%. In an even more preferred embodiment, the active carotenoid component of the composition is in the range of 0.1% to 10% by weight and more preferably 1% to 5% by weight.

In yet a further preferred form of the invention, the carrier medium used to carry the water insoluble carotenoid component is selected from the group comprising fatty acids and triglyceride lipids and non-saponifiable lipid preparations, certain suitable petroleum hydrocarbons including octadecane and combinations of the foregoing compounds.

In yet a further preferred form of the invention, the triglyceride lipids are selected from the group comprising fats and/or oils derived from plant sources such as seed oils including soya bean, cotton seed and sunflower and from animal sources including fish and beef. More preferably, the carrier medium is in the range of 0.1% to 40% by weight and even more preferably 1% to 20%.

In a preferred form of the invention, the agent is diluted for direct introduction into the bloodstream or melanoma or melanomas and more preferably, the diluting solution is selected from aqueous buffers, normal intravenous preparations (including isotonic saline or 5% dextrose solution) and blood serum and combinations of the foregoing for administration to cells in vivo and cell line culture media for administration to cells in vitro.

In a further form of the invention, a method of treatment of a melanoma or melanomas is provided including the step of introducing directly into the bloodstream or melanoma or melanomas, an effective amount of a therapeutic agent as described above. Preferably, the effective amount is from 0.1 to 10.0 micrograms/ml and more preferably, 0.3 to 3.0 micrograms/ml of the therapeutic agent contacting the melanoma cells.

More preferably, the therapeutic agent is directly introduced into the bloodstream by injection or intravenously. Even more preferably, the therapeutic agent is injected directly into the site of the melanoma or melanomas.

The term "mixture" as used herein is intended to include various physical forms including emulsions, solutions and crystal suspensions.

Examples

5 The following examples demonstrate the effectiveness of carotenoid compositions in the treatment of melanomas and the relative non-toxicity of those compositions.

Figure 1 are graphs showing the effect of carriers on DNA synthesis in human metastatic melanoma and neonatal melanocytes. In summary, the melanoma cell strain, c81-46a and melanocytes were incubated for 72 hours with soybean oil extract, tetrahydrofuran and a 3:1 mixture of dimethylsulfoxide:ethanol. Each data point is the mean of 6 wells +/- percent standard error as compared to control.

Figure 2 is a graph showing the effect of beta-carotene on DNA synthesis in human metastatic melanoma and neonatal melanocytes. In summary, melanoma cell strains: c83-2c, c81-46c, c81-46a, c81-61 and melanocytes (MC) were incubated for 72 hours with beta-carotene. Each data point is the mean of 6 wells +/- percent standard error as compared to control. Diluent (soy) concentration = 0.05%.

Figure 3 is a graph showing the effect of beta-carotene on the proliferation of human metastatic melanoma and neonatal melanocytes. In summary, melanoma cell strains: c83-2c, c81-46c, c81-46a and melanocytes (MC) were incubated for 72 hours with beta-carotene and viability assessed by trypan blue exclusion. Each data point is the mean of 3 wells +/- percent standard error as compared to control. Diluent (soy) concentration = 0.05%.

Figure 4 is a graph showing the effect of beta-carotene on DNA synthesis in human tumor and normal cell lines. In summary, A431, epidermoid carcinoma; WiDr, colon adenocarcinoma; WI-38, fetal lung fibroblasts and Lu-CSF-1, lung adenocarcinoma were incubated for 72 hours with beta-carotene. Each data point is the mean of 6 wells +/- percent standard error as compared to control. Diluent (soy) concentration = 0.05%.

Figure 5 is a graph showing the effect of 9-cis Beta Carotene on DNA synthesis in human metastatic melanoma and neonatal melanocytes. In summary, the melanoma cell strain c81-46a and melanocytes were incubated for 72 hours with 9-cis beta-carotene. Each data point is the mean of 6 wells +/- percent standard error as compared to control. Diluent (soy) concentration 0.05%.

Figures 1, 2 and 4 refer to "Percent Tritiated Thymidine Incorporation" which is a measure of DNA synthesis activity.

Details of the experiments conducted in relation to the invention are as follows.

Materials

(a) Cell Cultures

- The method used to isolate and culture melanocytes is a combination of the procedures developed by Eisinger and Marko (see Eisinger M, Marko O: Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci 79:2018-2022, 1982) and Halaban and Alfano (see Halaban R, Alfano FD: Selective elimination of fibroblasts from cultures of normal human melanocytes. In Vitro 20:45-47, 1984).
- 5 Briefly, foreskin samples were collected from newborn infants, and the melanocytes isolated and transferred to a T-75 flask. Primary neonatal melanocytes were cultivated in MCDB 153 medium (Irvine Sci.) as described by Halaban (see Halaban R, Ghosh S, Baird A: bFGF is the putative natural growth factor for normal human melanocytes. In Vitro Cell Develop Biol 23:47-52, 1987) and modified by Kath (see Kath R, Rodeck U, Menssen HD et al: Tumor progression in the human melanocytic system: Anticancer Res 9:865-872, 1987). Fibroblast contamination was suppressed by adding geneticin (250 micrograms/ml) to the medium for 2 days. Melanoma cell strains (c81-46a, c81-46c, c81-61, c83-2c) were cultured in F-10 (Fisher sci.) with 5% fetal calf serum, 5% newborn calf serum (Gemini Sci.), penicillin (100 units/ml) and streptomycin (0.1 milligrams/ml) (Sigma). The passage number for the melanoma cell strains used was less than 8, and the melanocytes was less than 5. The melanoma cell strains have previously been characterised (see Bregman MD, Meyskens FL: Inhibition of human malignant melanoma colony-forming cells in vitro by prostaglandin A1, Canc Res 43:1642-1645, 1983; Thomison SP, Meyskens FL: Methods of measurement of self-renewal capacity of clonogenic cells from biopsies of metastatic human malignant melanoma. Canc Res 42:4606-4613, 1982; and Yohem KH, Slymen DJ, Bregman MD, et al: Radiation survival of murine and human melanoma cells utilizing two assay systems; monolayer and soft agar. Br J Canc 57:64-69, 1987). A number of other tumour cell lines were also tested namely, A-431 (a human epidermoid carcinoma), WiDr (a human colon adenocarcinoma), 25 WI-38 (normal human fetal lung fibroblasts) (all obtained from the American Type Culture Collection) and Lu-CSF-1 (a human lung adenocarcinoma) (provided by the University of California at Irvine). These four cell lines were cultured in DMEM medium (Fisher Sci.), 5% fetal calf serum, 5% newborn calf serum, penicillin (100 units/ml) and streptomycin (0.1 milligrams/ml).
- 30

(b) Chemicals

The beta-carotene was isolated from the alga *Dunaliella salina* and represented 85-90% of the total carotenoids, with half of the balance consisting of oxycarotenoids (lutein and zeaxanthin) and the remaining half of alpha-carotene. Gamma-carotene is normally undetectable as characterised by high pressure liquid chromatography. The soya bean oil was isolated from soya beans. A crystalline suspension of beta-carotene and soya bean oil was created. This resultant phase was then emulsified into the composition described. It was then sterilised by heat or filtration. Prior to testing on the cell lines each vial of the composition was sub-aliquoted into cryogenic vials (Costar) with a fresh vial used for each experiment. Throughout all procedures, beta-carotene was protected from direct light.

Tetrahydrofuran and ethanol (Fisher Sci.) of the highest quality available was used. Dimethylsulfoxide was purchased from Sigma.

The details of the emulsified beta-carotene composition are as follows:

		% by weight
15	(i) Beta-carotene	2.4%
	and	
	(ii) SOY being:	
	Soya bean oil	6.8%
	Glyceryl mono-oleate	7.2%
20	Glycerol	66.7%
	Water	16.9%

The above composition can be prepared by the following method. A crystalline suspension of beta-carotene in soya bean oil is heated and glyceryl mono-oleate is added. This oil phase is dispersed in the glycerol-water phase by high shear mixing followed by homogenisation at 60-70°C. Typically, a homogenisation pressure of 8,000 to 10,000 PSI is used, however, this pressure will vary according to the machine that is used. The resulting product is then sterilized by heat processing. Typically, heat processing is effected by autoclaving at 121°C for 15 minutes in a pack for dispensing (3ml glass vial). Optionally, 0.3% of the anti-oxidant tocopherols is added to overcome any toxicity that may develop over a period of time.

(c) **Experimental Conditions**

Incorporation of tritiated thymidine into DNA was measured in the following manner. Cells were seeded into a 96 well plate (Falcon) and allowed to grow to 50% confluency (24 hours) after which fresh medium alone, fresh medium with beta-carotene or fresh medium
5 with a carrier (carrier concentration = 0.05%) were added and incubated for 72 hours. DNA synthesis was measured by labelling with [methyl-3H]-thymidine (2.5uCi/ml, 20Ci/mmol Dupont-New England Nuclear) added to the medium during the last 15 hours of the treatment period. After incubation, cells were harvested using a PhD cell harvester (Cambridge Research Inc.). Radioactivity incorporated was determined by liquid
10 scintillation counting (LS5000TD, Beckman Instruments) with an efficiency of 62.7%. The data is represented as percent tritiated thymidine incorporation as compared to control. Each data point is the mean of 6 wells +/- percent standard error.

Cellular proliferation was determined as follows. Cells were seeded into 6 well plates (Falcon) and allowed to grow to 50% confluency (24 hours). Fresh medium and the
15 appropriate compound was added and cells then incubated for 72 hours. After incubation, cells were harvested with 0.25% trypsin and washed. Cells were counted on a Coulter Counter (Coulter Instruments) and viability determined by trypan blue exclusion. Each data point is the mean of 3 wells +/- percent standard error.

Results

20 To determine the effect of a number of carriers for beta-carotene on the activity of normal melanocytes and a metastatic melanoma cell strain, c81-46a thymidine incorporation was measured. Tetrahydrofuran ("THF"), a 3:1 mixture of dimethylsulfoxide/ethanol ("DMSO/ETOH") and the SOY were incubated with the cells for 72 hours at 0.005%, 0.05% and 0.5% concentration.

25 As shown in figure 1, the SOY did not effect incorporation of thymidine in the melanoma cells at any concentration of the diluent. THF had only a slight effect on the melanoma cells, while DMSO/ETOH decreased incorporation by 40% at the highest concentration.

Figure 2 shows the effect of beta-carotene in the SOY carrier on normal melanocytes and four metastatic melanoma cell strains. At a concentration of 0.1 micrograms/ml,
30 beta-carotene had a slight inhibitory effect on the melanoma cell growth. The most sensitive being c81-61 with a 20% decrease in DNA synthesis. However, the melanomas showed a differential response to beta-carotene at 1.0 micrograms/ml, ranging from no inhibition to greater than 40%. At the highest beta-carotene concentration (10

micrograms/ml), normal melanocytes and two of the melanomas (c81-61, c81-46c) were more than 95% inhibited. Although, c81-46a and c83-2c remained 20-25% unaffected.

Additionally, viability, as measured by trypan blue exclusion, of normal melanocytes and the four metastatic melanomas was determined (figure 3). Beta-carotene at 1.0
5 micrograms/ml reduced viability by 20% while at 10 micrograms/ml no viable melanocytes were detected. Most striking is beta-carotene at the highest dose, which resulted in no viable melanocyte cells and 60% of the melanomas unaffected.

The response of other tumor types was also assessed for their response to beta-carotene (figure 4). The human epidermoid carcinoma cell line, A-431, was unaffected by
10 beta-carotene even at 10 micrograms/ml. The colon cell line, the normal lung fibroblasts and the lung adenocarcinoma cell line were minimally inhibited (10-20%).

Figure 5 shows the effect of 9-cis beta carotene in the SOY carrier on normal melanocytes and one metastatic melanoma cell strain. At a concentration of 1.0 microgram/ml, both the normal melanocyte and the c81-46a were approximately 50% inhibited. At the higher
15 concentration of 9-cis beta carotene (10.0 micrograms/ml), the metastatic melanoma cell strain was 90% inhibited while the melanocyte was slightly less inhibited than at 1.0 microgram/ml.

Without wishing to be limited to any specific theory, it appears that the mixture as illustrated in the above illustrations is a superfine emulsion.

20 In vitro studies to date have employed various chemical solvents as the carrier for beta-carotene. It has been found that the effect of these solvents alone is cytotoxic. The current testing as set out above has revealed that as measured by tritiated thymidine incorporation, the SOY did not effect the growth of normal human melanocytes or metastatic melanoma cell strains. However, solvents such as THF and a DMSO/ETOH
25 mixture inhibited DNA synthesis in a concentration dependent manner.

As a novel carrier for beta-carotene, the SOY allowed the effect of beta-carotene to be measured without the confounding toxicity of a harsh solvent carrier that interferes with the response.

Melanocytes were selected as a human cell type which is sensitive to inhibition by a range
30 of chemicals. The test results indicated that SOY did not inhibit incorporation of tritiated thymidine into the melanocyte DNA or the cell viability as determined by trypan blue exclusion.

Melanomas while typically not as sensitive to inhibition by a range of chemicals as melanocytes, were even more sensitive to even moderate levels of beta-carotene. This indicated a differential effect for melanomas.

The claims defining the invention are as follows:

1. A therapeutic agent for the treatment of a melanoma or melanomas including a mixture of:
 - (a) a water soluble or dispersible component;
 - 5 (b) an emulsifier component; and
 - (c) a water insoluble carotenoid component in a suitable carrier medium.
2. A therapeutic agent according to claim 1 wherein the water soluble or dispersible component is in the range of 30% to 90% by weight.
3. A therapeutic agent according to claim 1 or 2, wherein the water soluble or
10 dispersible component is selected from sugar alcohols, sugars, amino acids, water, vitamins, blood serum or plasma, lymph, buffers and combinations and polymers of these materials, and injectables such as mineral salt preparations and dextrose solutions or combinations of these components.
4. A therapeutic agent according to claim 3 wherein the sugar alcohol is glycerol.
- 15 5. A therapeutic agent according to claim 4, wherein the glycerol is in the range of 30% to 90% by weight.
6. A therapeutic agent according to any one of claims 1 to 5, wherein the emulsifier component is in the range of 0.2% to 20% by weight.
7. A therapeutic agent according to any one of claims 1 to 5, wherein the emulsifier
20 component is in the range of 1.0% to 10% by weight.
8. A therapeutic agent according to any one of claims 1 to 7, wherein the emulsifier component is selected from glycerides (including mono and diglyceride structures from plant and animal sources), polyglycerol esters, lecithins and other phospholipids.
- 25 9. A therapeutic agent according to claim 8, wherein the glyceride is glyceryl mono-oleate.
10. A therapeutic agent according to any one of claims 1 to 9, wherein the water insoluble carotenoid component is predominantly beta-carotene.
- 30 11. A therapeutic agent according to any one of claims 1 to 9, wherein the water insoluble carotenoid component is predominantly a 2% to 50% by weight beta-carotene in soya bean oil composition.

12. A therapeutic agent according to claims 1 to 9, wherein the water insoluble carotenoid component is predominantly a 20% to 40% by weight beta-carotene in a soya bean oil composition.
13. A therapeutic agent according to claims 1 to 9, wherein the water insoluble carotenoid component is predominantly a 30% by weight beta-carotene in a soya bean oil composition.
14. A therapeutic agent according to any one of claims 10 to 13, wherein the beta-carotene is a mixture of cis beta-carotene and all trans beta-carotene.
15. A therapeutic agent according to claim 14, wherein the cis beta-carotene content of the beta-carotene is in the range of 50% and 90%.
16. A therapeutic agent according to claim 14, wherein the cis beta-carotene content of the beta-carotene is in the range of 70% and 85%.
17. A therapeutic agent according to any one of claims 14 to 16, wherein the cis beta-carotene content is predominantly 9 cis beta-carotene.
18. A therapeutic agent according to any one of claims 14 to 16, wherein the cis beta-carotene content is in the range of 60% to 90% 9 cis beta-carotene.
19. A therapeutic agent according to any one of claims 1 to 18, wherein the water insoluble carotenoid component of the composition is in the range of 0.1% to 10% by weight.
20. A therapeutic agent according to any one of claims 1 to 18, wherein the water insoluble carotenoid composition is in the range of 1% to 5% by weight.
21. A therapeutic agent according to any one of claims 1 to 20, wherein the carrier medium used to carry the water insoluble carotenoid component is selected from the group comprising fatty acids and triglyceride lipids and non-saponifiable lipid preparations, petroleum hydrocarbons including octadecane and combinations of the foregoing compounds.
22. A therapeutic agent according to claim 21, wherein the triglyceride lipids are selected from the group comprising fats and/or oils derived from plant sources including seed oils including soya bean, cotton seed and sunflower and from animal sources including fish and beef.
23. A therapeutic agent according to any one of claims 1 to 22, wherein the carrier medium is in the range of 0.1% to 40% by weight.

24. A therapeutic agent according to any one of claims 1 to 22, wherein the carrier medium is in the range of 1% to 20% by weight.
25. A therapeutic agent according to any one of claims 1 to 24, wherein the agent is diluted for direct introduction into the bloodstream or melanoma or melanomas of an effective amount of the composition.
26. A therapeutic agent according to any one of claim 25, wherein the agent is diluted by aqueous buffers, normal intravenous preparations (including isotonic saline or 5% dextrose solution) and blood serum or combinations of the foregoing.
27. A method of treatment of a melanoma or melanomas including the step of introducing directly into the bloodstream or melanoma an effective amount of a therapeutic agent according to any one of claims 1 to 26.
28. The method of treatment of a melanoma or melanomas according to claim 27, wherein the effective amount is from 0.1 to 10.0 micrograms/ml of the therapeutic agent contacting the melanoma cells.
29. The method of treatment of a melanoma or melanomas according to claim 27, wherein the effective amount is from 0.1 to 3.0 micrograms/ml of the therapeutic agent contacting the melanoma cells.
30. A method of treatment of a melanoma or melanomas according to any one of claims 27 to 29, wherein the introduction of the therapeutic agent into the bloodstream is by injection or intravenously.
31. A method of treatment of a melanoma or melanomas according to any one of claims 27 to 29, wherein the introduction of the therapeutic agent directly into the site of the melanoma or melanomas is by injection.




Figure 1

2/5




Figure 2

3/5




Figure 3

4/5




Figure 4

5/5





Figure 5

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. ⁵ A61K 9/107, 31/015, 31/355 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC A61K 9/107 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU:IPC as above Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) DERWENT: CAROTEN:OR VITAMIN E OR TOCOPHEROL CAROTEN:OR VITAMIN E OR TOCOPHEROL AND CAS: EMULSION AND INTRAVEN:OR INJECT:OR PHARMAB:OR MEDICIN:				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.		
X Y	WO,A,92/05780 (BRIGHAM AND WOMEN'S HOSPITAL) 16 April 1992 (16.04.92) page 10 line 25 to page 11 line 6.	1-3,10,11-21,22-26 1-26		
Y	EP,A,494654 (KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA) 15 July 1992 (15.07.92) continued...	1-26		
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex: </div>				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> * Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle of theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </table>			* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle of theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle of theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search 15 June 1994 (15.06.94)		Date of mailing of the international search report 22 June 1994 (22.06.94)		
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No. 06 2853929		Authorized officer  J.G. HANSON Telephone No. (06) 2832262		

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate of the relevant passages	Relevant to Claim No.
Y	AU,B,56222/90 (633320) (ABBOTT LABORATORIES) 10 January 1991 (10.01.91)	1-26
Y	AU,A,86922/91 (FUJISAWA PHARMACEUTICAL CO., LTD) 7 May 1992 (07.05.92)	1-26
Y	AU,B,61646/86 (595824) (MICROBIO RESOURCES, INC) 5 March 1987 (05.03.87) page 3a lines 8-12	1-26
Y	AU,B,34011/84 (566215) (BIOLAN LAB. (AUST.) PTY, LTD. AND BIOGLAN INC.) 7 November 1985 (07.11.85)	1-26
Y	AU,B,37822/89 (614640) (KYORIN SEIYAKU KABUSHIKI KAISHA) 18 January 1990 (18.01.90)	1-26
Y	AU,B,63591/90 (629983) (THE UNIVERSITY OF NOTTINGHAM) 3 April 1991 (03.04.91)	1-26
A	EP,A,479066 (BASF AG) 8 April 1992 (08.04.92)	

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
WO	9205780	AU HU	88621/91 9300950	CA JP	2093008 6501695	EP	551427
EP	494654	CA JP	2058835 5078240	JP US	5078235 5298246	US	5298246
AU	56222/90	CA JP	2018096 3047119	EP	400547	US	5196198
AU	86922/91	CA JP	2054629 5009117	EP	483842	HU	60924
AU	61646/86	IL	79850	US	4680314		
AU	34011/84	CA NZ	1254140 209526	EP US	165352 4572915	JP	60233010
EP	479066	CA	2051978	DE	4031094	JP	4247028
AU	37822/89	EP	350913	HU	52380		
AU	63591/90	CA JP	2064190 5500062	DE WO	69008729 9102517	EP DE	487636 69008729
END OF ANNEX							

